Ablation of Neuroaxial in Patients with Ventricular Tachycardia

Ventricular tachycardia (VT) remains a common cause of sudden cardiac death. It is widely accepted that VTs are strongly associated with autonomic imbalance with reduced vagal and increased sympathetic activities. Pharmacologic therapy remains the first-line therapy, but antiarrhythmic agents may not be effective or carry significant side effects. Sympathetic denervation is an emerging therapy to prevent or treat VTs by rebalancing the sympathetic and parasympathetic activity. This article focuses on the role of sympathetic activation in VT, and the mapping and ablation of sympathetic nervous system in patients with VT.